SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-160789
Filing Date
2023-06-05
Accepted
2023-06-05 17:01:54
Documents
14
Period of Report
2023-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d508323d8k.htm   iXBRL 8-K 29950
2 EX-10.1 d508323dex101.htm EX-10.1 58304
3 EX-10.2 d508323dex102.htm EX-10.2 67464
  Complete submission text file 0001193125-23-160789.txt   310414

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA acrv-20230530.xsd EX-101.SCH 2838
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20230530_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20230530_pre.xml EX-101.PRE 11699
8 EXTRACTED XBRL INSTANCE DOCUMENT d508323d8k_htm.xml XML 3459
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 23993555
SIC: 2834 Pharmaceutical Preparations